Stockreport

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

Agilent Technologies, Inc.  (A) 
Last agilent technologies, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NYSE Investor Relations: investor.agilent.com
PDF Approval expands first-line PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies [Read more]